Клиническая эффективность биологически активной добавки «Цыгапан» в комплексе реабилитации детей, больных бронхиальной астмой
Л. Н. Буркастова, Юрий Леонидович Мизерницкий, Л. В. Соколова et al. · Педиатрическая фармакология · 2003
The above-mentioned children's pulmonological sanatorium was used as the base for carrying out a double-blind comparative placebo-controlled study of clinical efficiency of biologically active additive «Tsygapan» in 7-to-14-year-old children with mild-to-moderate bronchial asthma. All the children (randomly assigned to 2 groups, each consisting of 20 subjects) were undergoing a rehabilitation course under the sanatorium conditions, with the study group additionally receiving «Tsygapan», while the control group children being given a placebo during 21 days. By the moment of the study, the children were in the remission stage, regularly receiving the basic anti-asthmatic therapy, which remained unaltered on the background of the whole course of the sanatorium-rehabilitation course. The children’s condition was satisfactory, with no alterations in their blood counts being observed. The researchers assessed the dynamics of the external respiration indices, test for physical load, cardiointervalography (before and after the rehabilitation course), dynamics of the circadian fluctuations in the indices of peak flowmetry, incidence of seizures, as well as adverse effects. The obtained findings showed that the use of Tsygapan promoted stabilisation of the children’s condition at the expense of significantly larger decrease in the circadian variations of the peak expiration rate ( by data of peak flowmetry), more pronounced normalisation of the vegetative status (by data of cardiointervalography), which decreased the effect of the vegetative component on development of asthmatic attacks. Besides, a more pronounced trend was observed towards normalisation of other rate-related indices of external respiration in the children receiving Tsygapan. Neither side effects, nor allergic reactions were observed. Hence, it is safe to recommend inclusion of biologically active supplement «Tsygapan» into comprehensive sets of therapeutic and health-promoting measures in children suffering from bronchial asthma.
Cited by 0 works.